Status:
COMPLETED
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
Lead Sponsor:
Fougera Pharmaceuticals Inc.
Conditions:
Psoriasis
Atopic Dermatitis
Eligibility:
All Genders
3+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either...
Eligibility Criteria
Inclusion
- Clinical diagnosis of psoriasis or atopic dermatitis involving more than 20% of body surface area
- Good health with the exception of psoriasis or atopic dermatitis
Exclusion
- Any disease affecting the HPA-axis
- Subjects who are pregnant, nursing, or planning a pregnancy within the study participation period
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT01137032
Start Date
June 1 2004
End Date
August 1 2005
Last Update
May 4 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Christopher Huerter, MD
Omaha, Nebraska, United States, 68130
2
Oswald Mikell, MD
Hilton Head Island, South Carolina, United States, 29926
3
Michael Gold, MD
Nashville, Tennessee, United States, 37215